Tech Center 1600 • Art Units: 1632 1638
This examiner grants 42% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19361281 | ADENO-ASSOCIATED VIRAL VECTOR COMPOSITIONS AND METHODS OF USE | Non-Final OA | Siren Biotechnology, Inc. |
| 18437160 | GENETICALLY MODIFIED MSC AND THERAPEUTIC METHODS | Final Rejection | The Regents of the University of California |
| 17351113 | METHODS FOR THE TREATMENT OF DANON DISEASE AND OTHER DISORDERS OF AUTOPHAGY | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17910992 | NK CELLS AND USES THEREOF FOR TREATMENT OF MICROBIAL INFECTIONS | Non-Final OA | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 16624081 | A METHOD OF TREATING EPIDERMOLYSIS BULLOSA USING MUSE CELLS | Non-Final OA | TOHOKU UNIVERSITY |
| 18052113 | TRANSGENIC RABBIT WITH COMMON LIGHT CHAIN | Non-Final OA | Hoffmann-La Roche Inc. |
| 17676338 | NON-HUMAN ANIMALS HAVING AN IMMUNOGLOBULIN HEAVY CHAIN VARIABLE REGION THAT INCLUDES AN ENGINEERED DIVERSITY CLUSTER AND USES THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17168708 | MICE THAT MAKE VL BINDING PROTEINS | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 17113485 | GENETICALLY MODIFIED MICE THAT EXPRESS HUMANIZED IgG1 LACKING A CH1 DOMAIN AND HUMANIZED UNIVERSAL LIGHT CHAIN | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17041252 | GENETICALLY MODIFIED NON-HUMAN ANIMALS FOR GENERATING THERAPEUTIC ANTIBODIES AGAINST PEPTIDE-MHC COMPLEXES, METHODS OF MAKING AND USES THEREOF | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 16991283 | GENETICALLY MODIFIED MAJOR HISTOCOMPATIBILITY COMPLEX MICE | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 18006969 | BLADDER ORGANOID AND METHOD FOR PRODUCING SAME | Non-Final OA | OTSUKA PHARMACEUTICAL CO., LTD. |
| 17910776 | METHODS FOR GENERATING ENGINEERED MEMORY-LIKE NK CELLS AND COMPOSITIONS THEREOF | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 17640585 | DEVELOPMENT OF EMBRYONIC-LIKE TISSUE FROM STEM CELLS | Final Rejection | The Regents of the University of Michigan |
| 19088744 | VIABLE GALACTOSYLTRANSFERASE KNOCK-OUT SHEEP AND RELATED METHODS | Non-Final OA | FIOS THERAPEUTICS, LLC |
| 18033442 | MOUSE MODEL FOR BIO-IMAGING OF INFLAMMATORY SIGNALS, PREPARATION METHOD THEREFOR AND USE THEREOF | Non-Final OA | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION |
| 17763849 | SYSTEMS AND METHODS FOR BATCH CULTIVATION OF NON-TRANSGENIC HETEROGAMETES | Final Rejection | REGENTS OF THE UNIVERSITY OF MINNESOTA |
| 16477110 | Methods of Treating Brain Injury Using Cord Blood or a Component Thereof | Non-Final OA | Duke University |
| 18015043 | TRANSGENIC MOUSE MODEL EXPRESSING HUMAN HLA-A201 RESTRICTION GENE | Non-Final OA | The Jackson Laboratory |
| 17604545 | GENE THERAPIES FOR USHER SYNDROME (USH2A) | Non-Final OA | University of Massachusetts |
| 17915548 | AAV CAPSIDS VARIANTS AND USES THEREOF | Final Rejection | Sichuan University |
| 18132164 | COMPOSITIONS, METHODS AND USES FOR IN VITRO AND IN VIVO GENERATION OF FUNCTIONAL THYMIC TISSUE | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE |
| 16585184 | ADDITIVE FOR UNDIFFERENTIATION MAINTAINING MEDIUM | Final Rejection | KEIO UNIVERSITY |
| 18404213 | Somatic Cell Reprogramming | Final Rejection | Wisconsin Alumni Research Foundation |
| 17345773 | Methods for Cardiac Fibroblast Differentiation of Human Pluripotent Stem Cells | Final Rejection | Wisconsin Alumni Research Foundation |
| 18146644 | METHOD OF NUCLEAR REPROGRAMMING | Non-Final OA | Kyoto University |
| 17264752 | GENE THERAPY METHODS TO CONTROL ORGAN FUNCTION | Final Rejection | Cornell University |
| 17550051 | Use of FOXP3 Enhancers to Modulate Regulatory T Cells | Final Rejection | St. Jude Children's Research Hospital, Inc. |
| 17728927 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS | Non-Final OA | The Children's Medical Center Corporation |
| 17321645 | HIGHLY PARALLEL ASSAYS FOR SIMULTANEOUS IDENTIFICATION OF ANTIBODY SEQUENCES AND BINDING PARTNERS | Non-Final OA | THE UNIVERSITY OF BRITISH COLUMBIA |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy